demonstrating its feasibility. The possibility to use less intensified conditioning chemotherapy (for example, for elderly people) and to manage differently the aplastic phase after SCT is of extreme interest for the Authors and a matter of scientific challenge. 7 Here we report our experience of almost 20 years on autologous and allogeneic BMT offered to JW, with the aim to extrapolate a model of assistance.
As the reference Center for the South-East of Italy for JW, with overall 234 consultations since 1994, we have treated 75 patients for onco-hematological diseases. Twenty-two patients (15 males, 7 females; mean age 49 years, range 14-71 years; 86% under 60 years) have undergone SCT during the course of the disease, for a total of 24 procedures, and have been retrospectively included in the study. Patients gave written informed consent for the collection of clinical data, in accordance with the Declaration of Helsinki. Thirteen procedures were autologous and 11 allogeneic SCT. Seven patients had multiple myeloma (MM), three acute myeloid leukemia (AML), three follicular non-Hodgkin lymphomas (FL) grade 3, one classic Hodgkin's lymphoma (HL), one acute lymphoblastic leukemia (ALL), one lymphoblastic lymphoma (LBL), one primary myelofibrosis (MF), three chronic myeloid leukemia (CML), one in blastic phase, one Waldenstrom macroglobulinemia (WM) and one metastatic breast cancer (mBC). The SCT procedure was done as part of first-line therapy in six patients (two MM, two CML, two AML), second-line in nine patients (two NHL, two MM, one LBL, one MF, one CML in blastic phase, one ALL and one AML), third-line or more in seven patients (three MM, one NHL, one HL, one WM and one mBC). Two patients with MM received both autologous and allogeneic SCT. Conditioning regimens for autologous SCT were BEAM (carmustine, etoposide, aracytin and melphalan) for lymphomas and melphalan 200 mg/m 2 (140 mg/m 2 for patients older than 60 years) for MM. 8, 9 A myeloablative regimen was applied in the allogeneic setting for 6 patients: cyclophosphamide 120 mg/kg and TBI 12 Gy fractionate in LBL/ ALL; busulphan 14 mg/kg plus cyclophosphamide 120 mg/kg in AML and CML. In order to shorten the duration of therapy, without reducing the intensity, we made an overlap instead of sequential administration of drugs such as cyclophosphamide overlapping busulfan or thiotepa. MM and MF patients received reduced intensity conditioning (RIC) that consisted of thiotepa 10 mg/kg, cyclophosphamide 30 mg/kg and fludarabine 30 mg/m 2 for 2 days. We reinfused a minimum of 3 × 10 6 /kg for autologous and 5 × 10 6 /kg CD34+ hematopoietic stem cells (HSCs) for allogeneic SCT. The preferred source of HSCs was peripheral blood (11 autologous, 5 allogeneic SCT); bone marrow HSC were used in 1 autologous and 2 allogeneic SCT; we collected HCS from both sources when we predicted a delayed hematologic recovery or expected a drop of hemoglobin level putting life at risk; both peripheral and bone marrow HSC were used in one autologous and four allogeneic SCT. The donors for allogeneic SCT were siblings for nine patients and matched unrelated for two patients (Table 1) . Patients received epoetin alfa 1500 IU/kg three times a week, starting 3 days following the reinfusion of HSC up to hemoglobin 410 g/dL (median of 22 and 18 days of treatment for allogeneic and autologous SCT, respectively). The use of lenograstim (5 mcg/Kg/day) was limited to patients without recovery of PMN after 2 weeks from SCT. Patients were monitored by blood tests every 3 days in order to avoid excess blood consumption; daily monitoring of life parameters were ensured together with cardiac check in case of severe anemia. Engraftment of PMN was reached at a median time of 13 days (range 10-30 days) for non myeloablative and RIC and of 14 days (range 12-18 days) for myeloablative procedures. Failure of engraftment was recorded in two patients: one had received allogeneic SCT for secondary AML and died of sepsis by Pseudomonas aeruginosa; and one had received autologous SCT for WM and died of infection by Pneumocystis jirovecii. The nadir of hemoglobin was 1.7 g/dL for allogeneic SCT and 2.4 g/dL for autologous SCT. The patient (primary MF) with hemoglobin 1.7 g/dL finally accepted transfusions and is alive in CR at 1 year from allogeneic SCT. The patient (AML) with hemoglobin 2.4 g/dL at nadir recovered from autologous SCT, but died due to relapse. Two other patients (allogeneic SCT for ALL/LBL) were transfused with packed red cells and platelets when hemoglobin dropped below 5.0 g/dL and platelets under 5 × 10 3 /μL, but the course of disease was negative for early progression. Only one patient (autologous SCT) accepted platelet transfusions for a count o1 × 10 3 /μL. Treatment-related mortality ( o100 days from SCT) was 15% (2/13) for the autologous setting, 20% (1/5) for the myeloablative allogeneic setting and 14% (1/7) for the RIC. At last follow-up, five patients (three after allogeneic and two after autologous SCT) are alive and in CR and eight patients (six after autologous and one after allogeneic SCT) are alive, but with the disease. Eight patients died because of the disease. One patient (WM) died of congestive heart failure due to anemia at day +23 and one patient (AML) of sepsis and renal failure ( Table 2 ). Median OS was 32 months (range 5-183 months) for patients in CR and 16 months (range 3-38 months) for patients with persistence of disease.
Despite the refusal of transfusions, autologous and allogeneic SCT in JW is feasible, independently of the conditioning regimen used. Our policy for allogeneic SCT is to shorten the duration of therapy, without reducing the therapeutic impact. The strategy of administering high-dose epoietin allows a more rapid recovery of the erythroid series and seems not to negatively influence the recovery of PMN and platelets. The recovery of erythropoiesis occurred rapidly, and a serious acute cardiac event was reported only in a patient. Hemorrhages were limited and controlled by local interventions. Only a few patients accepted transfusion in the presence of symptoms of anemia and thrombocytopenia and the number of transfused units was extremely small. Our experience demonstrates that the need for transfusions is prevalent for those patients with a disease heavily involving the bone marrow, for example, WM, MF or acute leukemia, and almost negligible for MM, lymphomas and mBC patients, who showed a faster recovery. This point is important to generate a model in which transfusions could be avoided or limited, and is well highlighted in previous works.
1,2 Costs of increased supportive therapy with epoietin alfa are not relevant, considering the short period of administration and the saving obtained by avoiding transfusions, which also have a sustained cost. We did not use alternative approaches, such as expansion of HSC or artificial blood components, because these methods are not currently available at our Institution. Treatmentrelated mortality was closely dependent on disease status; with the worst outcome for patients with refractory disease.
We can therefore conclude that transfusion-free SCT in JW is feasible in selected patients. Abbreviations: A = anemia; D = persistent disease; OS = overall survival; SCT = stem cell transplant; T = toxicity.
